■鲍曼不动杆菌引起的感染,特别是那些对抗生素如碳青霉烯耐药的药物,已经成为全球健康危机,死亡率很高。由鲍曼不动杆菌-钙乙酸(ABC)复合体引起的医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)代表了主要的临床挑战。本次审查旨在了解审批流程,作用机制,治疗潜力,舒巴坦-杜洛巴坦治疗(SUL-DUR)的未来意义。
■PubMed,WebofScience,EMBASE,临床试验。gov,ICTRP,和CENTRAL进行了SUL-DUR治疗医院获得性肺炎和呼吸机相关性肺炎的研究。此外,世界卫生组织,美国食品和药物管理局,和疾病控制和预防中心的网站被搜索相关信息。
■SUL-DUR,作为Xacduro销售,是一种新型药物组合,可作为窄谱胃肠外给药的抗生素。舒巴坦作为β-内酰胺酶抑制剂,而durlobacactam保护免受鲍曼不动杆菌酶的降解。1期试验成功确定了SUL-DUR在正常和轻度肾功能损害患者中的安全性和耐受性。一项2期试验证明了SUL-DUR在更大的尿路感染人群中的安全性和耐受性。一项3期试验表明,SUL-DUR在鲍曼不动杆菌相关VAP的死亡率方面不劣于粘菌素,HAP,和菌血症.
■舒巴坦和durlobactam的组合是ABC复合物引起的HAP和VAP的有希望的治疗选择。
UNASSIGNED: Infections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate. Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) resulting from the A. baumannii-calcoaceticus (ABC) complex represent a major clinical challenge. This review aimed to understand the approval process, mechanism of action, therapeutic potential, and future implications of
sulbactam-durlobactam therapy (SUL-DUR).
UNASSIGNED: PubMed, Web of Science, EMBASE, Clinical trials. gov, ICTRP, and CENTRAL were searched for studies on SUL-DUR for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Also, World Health Organization, U.S. Food and Drug Administration, and Centers for Disease Control and Prevention websites were searched for relevant information.
UNASSIGNED: SUL-DUR, marketed as Xacduro, is a novel pharmaceutical combination that functions as a narrow-spectrum parenterally administered antibiotic.
Sulbactam acts as a β-lactamase inhibitor, whereas durlobactam protects against degradation by A. baumannii enzymes. A phase 1 trial successfully established the safety and tolerability of SUL-DUR in patients with normal and mild renal impairment. A phase 2 trial demonstrated the safety and tolerability of SUL-DUR in a larger population with urinary tract infections. A phase 3 trial showed that SUL-DUR was non-inferior to colistin in terms of mortality in A. baumannii-related VAP, HAP, and bacteremia.
UNASSIGNED: The combination of
sulbactam and durlobactam is a promising treatment option for HAP and VAP caused by ABC complex.